NBIX – neurocrine biosciences, inc. (US:NASDAQ)

News

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
Neurocrine (NBIX) Reports Q1 Earnings: What Key Metrics Have to Say [Yahoo! Finance]
Neurocrine Biosciences Reports First Quarter 2024 Financial Results
UPDATE 1-Neurocrine Biosciences' Huntington's disease drug gets FDA approval [Yahoo! Finance]
Neurocrine Biosciences Announces U.S. FDA Approval of INGREZZA® SPRINKLE (valbenazine) Capsules [Yahoo! Finance]
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com